Sign In
Buy ALEC
$1.51
-0.110 (-6.79%)
At Close: Jul 31, 2026
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
07:00am, Tuesday, 28'th Nov 2023
Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to p
Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Tuesday, 14'th Nov 2023
The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
01:32pm, Friday, 08'th Sep 2023
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade
11:30am, Thursday, 10'th Aug 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positiv
Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates
07:32pm, Thursday, 03'rd Aug 2023
Alector (ALEC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to earnings of $0.12 per share a year ago.
Alector to Host Mid-Year Earnings Conference Call
08:30am, Thursday, 27'th Jul 2023
Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT
7 Stocks That AI Says Will Make You a Millionaire by 2025
01:29pm, Thursday, 13'th Jul 2023
Artificial intelligence technology is transforming many industries and creating new opportunities for businesses and consumers. But as an investor, how can you benefit from this powerful technology?
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
07:00am, Tuesday, 06'th Jun 2023
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partic
Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?
11:28am, Tuesday, 09'th May 2023
The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
09:17pm, Thursday, 04'th May 2023
Alector (ALEC) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.54 per share a year ago.
Alector: Trading At Cash Despite Late Stage CNS Pipeline
02:13pm, Friday, 03'rd Feb 2023
Alector, Inc. has a lot of cash for a small biotech, but it is also trading at cash. Alector, Inc. has a late-stage program in a CNS indication and major big pharma deals.
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates
09:04pm, Tuesday, 08'th Nov 2022
Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential
05:42am, Tuesday, 04'th Oct 2022
Initiation of phase 1 study of first clinical drug AL044 targeting MS4A for Alzheimer's Disease has been achieved. AbbVie for now remains committed with Alector in advancing AL002, which targets TREM2
Alector: Potential In Neurology And Cancer Treatments
01:29pm, Tuesday, 14'th Jun 2022
Results from the phase 3 INFRONT-3 study using AL001 for the treatment of patients with Frontotemporal dementia are expected in 2023. Alector holds the potential to advance AL001 for both FTD-GRN and
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
07:00am, Wednesday, 08'th Jun 2022
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partic
